Results 21 to 30 of about 125,192 (190)

Comparison of the Purity and Impurity of Glucagon-for-Injection Products under Various Stability Conditions

Scientia Pharmaceutica, 2022
Glucagon is a polypeptide hormone that serves as an essential therapeutic agent in the emergency treatment of hypoglycemia. Recently, the first generic glucagon for injection was approved. However, unlike its brand name counterpart, which is produced via
Zhongli Bao, Ya-Chi Cheng, Mary Ziping Luo, Jack Yongfeng Zhang   +3 more
doaj   +1 more source

Pancreatic hormones and amino acid levels following liver transplantation [PDF]

, 1987
Glucose intolerance, hyperinsulinemia, peripheral insulin resistance and hyperglucagonemia are common in patients with advanced liver disease. These abnormalities in the plasma levels of the pancreatic hormones, insulin and glucagon have been thought to ...
Chisholm, Collins, Collins, Conn, Creutzfeldt, Dudley, Eriksson, Fath, Fischer, Hahn, Hamish, Johnston, Kam, Kenny, Limberg, Marchesini, Marchesini, Marchesini, Marchesini, Megysi, Morgan, Muller, Nielsen, Pearly, Reilly, Robertson, Schander, Sherwin, Sherwin, Soeters, Starzl, Starzl, Trinder   +32 more
core   +1 more source

Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes [PDF]

, 2017
Postprandial hyperglycemia remains a challenge in type 1 diabetes (T1D) due, in part, to dysregulated increases in plasma glucagon levels after ...
Carria, Lori, Cengiz, Eda, Galderisi, Alfonso, Sherr, Jennifer, Tamborlane, William, Tichy, Eileen, Vanname, Michelle, Weinzimer, Stuart, Weyman, Kate, Zgorski, Melinda   +9 more
core   +1 more source

Enhancing endogenous levels of GLP1 dampens acute olanzapine induced perturbations in lipid and glucose metabolism

Frontiers in Pharmacology, 2023
Olanzapine is a second-generation antipsychotic (SGA) used in the treatment of schizophrenia and several on- and off-label conditions. While effective in reducing psychoses, acute olanzapine treatment causes rapid hyperglycemia, insulin resistance, and ...
Kyle D. Medak, Alyssa J. Weber, Hesham Shamshoum, Greg L. McKie, Margaret K. Hahn, Margaret K. Hahn, Margaret K. Hahn, Margaret K. Hahn, Margaret K. Hahn, David C. Wright, David C. Wright, David C. Wright   +11 more
doaj   +1 more source

Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans [PDF]

, 2006
Background: Exogenous use of the intestinal hormone glucagon-like peptide 1 (GLP-1) lowers glycaemia by stimulation of insulin, inhibition of glucagon, and delay of gastric emptying.Aims: To assess the effects of endogenous GLP-1 on endocrine pancreatic ...
Göke, Burkhard, Katschinski, M., Nicolaus, Mathias, Roggel, R., Schirra, Joerg, Storr, Martin, Woerle, H. J.   +6 more
core   +2 more sources

Case report: Fatal insulin overdose in a dog with type 1 diabetes mellitus—characteristics and successful management

Frontiers in Veterinary Science, 2023
Administering more than 10 times the therapeutic dose of insulin is extremely rare in diabetic dogs and is life threatening with hypoglycemia and seizures if not accompanied by appropriate treatment.
Jun-Hyeong Park, Ju-Hyun An, Se-Hoon Kim, Han-Sol Choi, Tae-Hyeon Kim, Ye-In Oh, Kyoung-Won Seo, Hwa-Young Youn   +7 more
doaj   +1 more source

Cyclic AMP metabolism and adenylate cyclase concentration in patients with advanced hepatic cirrhosis [PDF]

, 1978
Glucagon was tested for its effect on plasma adenosine 3′,5′-cyclic monophosphate (cyclic AMP), insulin, and glucose in healthy subjects and in patients with advanced cirrhosis of the liver. In the normal subjects, intravenous infusion of glucagon caused
Antonio Francavilla, Arthur F. Jones, Ball, Blonde, Bressler, Broadus, Broadus, Broadus, Brooker, Charles, Cherrington, Claycomb, Conn, Conn, Conn, Davies, Exton, Exton, Felig, Foa, Francavilla, Gilman, Hendy, Jerumo, Kaminsky, Kimmel, Krishna, Lambert, Lambert, Lambert, Levine, Liljenquist, Mackrell, Makman, Marco, McCullough, Milner, Miyamoto, Mori, Robison, Salomon, Sherwin, Srikant, Starzl, Strange, Strange, Sullivan, Sutherland, Taylor, Thomas E. Starzl, Turinsky, Turtle, Unger, Van Itallie, Vecchio, Verhaegen, Wahren, Walsh, White, Williams, Yalow, Zenser   +61 more
core   +1 more source

New uses and formulations of glucagon for hypoglycaemia

Drugs in Context, 2019
Hypoglycaemia is the more frequent complication of insulin therapy and the main barrier to tight glycaemic control. Injectable glucagon and oral intake of carbohydrates are the recommended treatments for severe and non-severe hypoglycaemia episodes ...
Pilar I Beato-Víbora, Francisco J Arroyo-Díez   +1 more
doaj   +1 more source

The LKB1-salt-inducible kinase pathway functions as a key gluconeogenic suppressor in the liver [PDF]

, 2014
LKB1 is a master kinase that regulates metabolism and growth through adenosine monophosphate-activated protein kinase (AMPK) and 12 other closely related kinases. Liver-specific ablation of LKB1 causes increased glucose production in hepatocytes in vitro
AK Al-Hakim, B Guigas, BL Williamson, C Kellendonk, C Kress, DG Hardie, DR Alessi, E Henriksson, G Rena, G Zhou, HV Lin, J Le Lay, J Luo, J Schaft, JA Vizcaino, JM Lizcano, JW Scott, JY Altarejos, K Clark, K Sakamoto, L Logie, L Ozcan, M Foretz, M Montminy, M Schuler, M Wan, MJ Sanders, MM Mihaylova, MN Berry, N Bardeesy, N Horike, O Goransson, P Tsou, R Dentin, RA Miller, RA Screaton, RJ Shaw, SH Koo, Y Wang, Z Wang   +39 more
core   +4 more sources

Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists [PDF]

, 2017
Type 2 diabetes mellitus (T2DM) leads to bone fragility and predisposes to increased risk of fracture, poor bone healing and other skeletal complications.
Chantal Chenu, Guillaume Mabilleau, Iepsen, Iepsen, Marie Pereira   +4 more
core   +3 more sources